However, there were questions about the validity of some of the research and the evidence was not sufficient for "prayer" to meet the criteria required for an "empirically supported treatment" in the United States.
Once more: I find it hard to understand how someone who worked as head of Research and Development at Pfizer could possibly deny this basic, universally recognised problem of poor external validity in clinical trials.